Gustave Roussy, Cancer Campus, Grand Paris

This study tested a combination of two drugs (rucaparib and atezolizumab) in 130 adults with advanced solid tumors that either had DNA repair defects or were sensitive to platinum chemotherapy. The goal was to see if the combination could shrink tumors. However, the trial was ter…

This study tested whether the drug olaparib could help people with advanced non-small cell lung cancer (NSCLC) who responded to initial chemotherapy. Participants who had a good response to platinum-based chemo were randomly assigned to take either olaparib or a placebo daily to …

This study tested a combination of two drugs, niraparib and dostarlimab, in adults with advanced solid tumors that either had DNA repair problems or were sensitive to platinum chemotherapy. The goal was to see how many patients' tumors shrank or disappeared. The trial was stopped…

This study tested two stronger treatment plans for children with a rare and aggressive nerve cancer called very high-risk neuroblastoma. It included 34 children whose cancer did not shrink enough after standard chemotherapy. The goal was to see if these intensified treatments cou…

This early-phase trial tested whether adding the immunotherapy drug durvalumab to standard chemotherapy is safe for people with advanced head and neck cancer. The study enrolled 14 adults with untreated, non-spread cancer. The goal was to find the best dose and check for side eff…

This study looked at whether giving a short course of immunotherapy (atezolizumab, alone or with other drugs) before standard treatment could boost the immune system's attack on early-stage breast cancer tumors. It included people with triple-negative or HER2-positive breast canc…

This pilot study aimed to see how consistently PET-MRI scans could map differences within lung tumors in people with advanced non-small cell lung cancer. Only 11 participants were enrolled before the study was stopped. The goal was to improve understanding of tumor heterogeneity,…